Drug
Difamilast clinical trials
Also written OPA-15406.
- studies test it
- 16
- open now
- 2
- in phase 3
- 10
- first study started
- 2012
Keep track of what changes. Save the difamilast studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Development codes
Studies by the year they started
16 studies that test it; most in 2019 (3)
| Year | Studies |
|---|---|
| 2012 | 1 |
| 2014 | 1 |
| 2015 | 1 |
| 2016 | 2 |
| 2017 | 1 |
| 2019 | 3 |
| 2022 | 3 |
| 2023 | 2 |
| 2025 | 2 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 2
- Phase 2
- 4
- Phase 3
- 10
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 16 · Other 0
Otsuka Pharmaceutical Co., Ltd. (9) · Otsuka Beijing Research Institute (2) · Acrotech Biopharma Inc. (2) · Otsuka Pharmaceutical Development & Commercialization, Inc. (2) · Medimetriks Pharmaceuticals, Inc (1)
Studies
Open first, then newest update. How each study uses difamilast is read from its arms, and is right about nine times in ten.
Testing it · 16
- A Phase 3 Trial of OPA-15406 Foam in Children and Infants With Atopic DermatitisNot yet recruitingPhase 3Otsuka Pharmaceutical Co., Ltd.NCT07184645Written as OPA-15406
- A Phase 3 Trial to Demonstrate the Superiority of 1% OPA-15406 Foam to the Vehicle in Adult Patients With Atopic DermatitisNot yet recruitingPhase 3Otsuka Pharmaceutical Co., Ltd.NCT07173478Written as OPA-15406
- To Demonstrate the Superiority of IMP (1% OPA-15406 Ointment) to the Vehicle in Adult Patients With ADCompletedPhase 3Otsuka Beijing Research InstituteNCT05667623Written as 1% OPA-15406 Ointment
- A Long-term Trial of OPA-15406 in Infants With Atopic DermatitisCompletedPhase 3Otsuka Pharmaceutical Co., Ltd.NCT05372653Written as OPA-15406
- To Demonstrate the Superiority of IMP (0.3% and 1% OPA-15406 Ointment) Versus the Vehicle in Pediatric Patients with ADCompletedPhase 3Otsuka Beijing Research InstituteNCT05650320Written as 0.3% OPA-15406 Ointment
- This Study is to Assess the Efficacy of Difamilast Ointment in Mild to Moderate Atopic Dermatitis(AD)CompletedPhase 3Acrotech Biopharma Inc.NCT05608343Written as Difamilast
- A Open-label Study to Assess the Long-term Safety of Difamilast Ointment 1% in Mild to Moderate Atopic DermatitisCompletedPhase 3Acrotech Biopharma Inc.NCT05571943Written as Difamilast
- A Study to Evaluate the Effectiveness and Safety of Topical OPA-15406 Ointment to Treat Participants With Atopic DermatitisCompletedPhase 2Otsuka Pharmaceutical Development & Commercialization, Inc.NCT02068352Written as OPA-15406
- Long-term Trial of OPA-15406 Ointment in Adult and Pediatric Patients With Atopic DermatitisCompletedPhase 3Otsuka Pharmaceutical Co., Ltd.NCT03961529Written as 0.3% OPA-15406 ointment
- Comparison Trial of OPA-15406 Ointment in Pediatric Patients With Atopic DermatitisCompletedPhase 3Otsuka Pharmaceutical Co., Ltd.NCT03911401Written as 0.3% OPA-15406
- Comparison Trial of OPA-15406 Ointment in Adult Patients With Atopic DermatitisSyndromeCompletedPhase 3Otsuka Pharmaceutical Co., Ltd.NCT03908970Written as 1% OPA-15406
- Phase 2 Study of OPA-15406 Ointment in Pediatric Patients With Atopic DermatitisCompletedPhase 2Otsuka Pharmaceutical Co., Ltd.NCT03018691Written as OPA-15406
- Study of OPA-15406 Ointment in Patients With Atopic DermatitisCompletedPhase 2Otsuka Pharmaceutical Co., Ltd.NCT02914548Written as OPA-15406
- Pharmacokinetics and Safety of MM36 Topical Ointment in Pediatric Subjects With Atopic DermatitisCompletedPhase 2Medimetriks Pharmaceuticals, IncNCT02945657Written as MM36 topical ointment, 1%
- A Phase 1 Trial of OPA-15406 Ointment in Healthy Adult Male SubjectsCompletedPhase 1Otsuka Pharmaceutical Co., Ltd.NCT02334787Written as 0.3% OPA-15406 Ointment
- A Safety Study to Evaluate the Use and Effectiveness of a Topical Ointment to Treat Adults With Atopic DermatitisCompletedPhase 1Otsuka Pharmaceutical Development & Commercialization, Inc.NCT01702181Written as OPA-15406
Codes
What other systems call difamilast · ClinicalTrials.gg INT001439
- MeSH (NLM) C000711049difamilastConfirmed ClinicalTrials.gov, NLM
- UNII (FDA) T3U32GLJ0FDIFAMILASTConfirmed FDA, NLM, Wikidata
- Wikidata Q105335086difamilastConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C169909DifamilastOne source FDA
- DrugBank DB14987One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000711049 | difamilast | Confirmed ClinicalTrials.gov, NLM |
| UNII (FDA) | T3U32GLJ0F | DIFAMILAST | Confirmed FDA, NLM, Wikidata |
| Wikidata | Q105335086 | difamilast | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C169909 | Difamilast | One source FDA |
| DrugBank | DB14987 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.